Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6,809 JPY | +1.04% | -0.50% | -12.87% |
May. 15 | Ibiden Co.,Ltd. Approves Year End Cash Dividends, Effective May 30, 2024 | CI |
Apr. 11 | Jefferies Starts Ibiden at Hold With 6,630 Yen Price Target | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Semiconductors
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.87% | 5.96B | B | ||
+159.36% | 3,176B | B- | ||
+75.38% | 829B | A- | ||
+53.57% | 792B | C | ||
+21.99% | 294B | B- | ||
+43.94% | 226B | B- | ||
+136.25% | 188B | - | ||
+18.36% | 184B | A- | ||
+53.35% | 148B | B+ | ||
+19.72% | 118B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4062 Stock
- Ratings Ibiden Co.,Ltd.